title: Molecularly-targeted Strategy and NF-κB in lymphoid malignancies.
abstract: Molecularly-targeted therapy is a promising strategy for the treatment of cancer. Nuclear factor (NF)-κB is a transcription factor that is constitutively activated in various lymphoid malignancies and may therefore be a good therapeutic target. Lymphoid malignancies arise from different stages of normal lymphocyte differentiation and acquire distinct pathways for constitutive NF-κB activation. However, no NF-κB inhibitor has yet been successfully applied in clinical medicine. This review focuses on the concept of molecularly-targeted therapeutics with small molecule drugs, molecular mechanisms of constitutive NF-κB activation in lymphoid malignancies, and the development of NF-κB inhibitors. A future perspective regarding the development of NF-κB inhibitors is also included.
authors.affiliation: Department of Hematology, School of Medicine, Kitasato University.
authors.forename: Ryouichi
authors.initials: R
authors.lastname: Horie
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007945:Leukemia, Lymphoid / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism*; D008223:Lymphoma / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism*; D058990:Molecular Targeted Therapy; D016328:NF-kappa B / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D016328:NF-kappa B